Clinical trials: Partial
Depression, Bipolar Disorder
Augmenting Hospitalization for Serious Mental Illness: Cognitive Bias Modification
Approximately 4.1% of the adult US population meets the criteria for SMI, a mental disorder associated with significant functional impairment.
- Conditions
- Depression, Bipolar Disorder, Anxiety Disorders, Psychiatric Disorder
- Trial name
- NCT03509181
- Testing
- I-Change, Symptom Tracking
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Mclean Hospital
Attention Deficit Hyperactivity Disorder
Treatment of Children With ADHD Who do Not Fully Respond to Stimulants
The purpose of this pilot is to initiate a program of research into the development of effective medication techniques to treat those children with ADHD who are referred because they are "partial" or "non-responders" to standard…
- Trial name
- TREAT (NCT00279409)
- Testing
- aripiprazole, Sugar pill
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New York State Psychiatric Institute
Reflux Episodes
TLESR-impedance Study in Patients
The purpose of the study is to compare frequency and content of reflux episodes in patients with gastroesophageal reflux disease.
- Trial name
- NCT00743444
- Testing
- AZD3355
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Psychiatric Illness, Healthy
Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness
The present study proposes to evaluate the potential cognitive enhancing effects of GLYX-13, an NMDAR partial agonist, among a group of healthy adults and those with psychiatric illness on a series of functional magnetic…
- Trial name
- NCT01844726
- Testing
- GLYX-13
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Chronic Obstructive Pulmonary Disease
Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant
The study will assess the Pharmacokinetic (PK) and safety of BGF MDI [Budesonide/glycopyrronium/formoterol (BGF) metered dose inhaler (MDI)] formulated with 2 different propellants :Hydrofluoroolefin (HFO) and Hydrofluoroalkane…
- Trial name
- NCT05477108
- Testing
- Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal)
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Partial Epilepsy, Catamenial Epilepsy
A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures
The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs).
- Trial name
- NCT00465517
- Testing
- Ganaxolone
- Where
- 27 sites in United States
- Volunteers
- 147 people
- Sponsor
- Marinus Pharmaceuticals
Deep Partial Thickness Burn
Effect of EGF With Silver Sulfadiazine Cream Compared With Silver Zinc Sulfadiazine Cream for Treatment of Burn Wound
Partial thickness burn wounds are most likely to heal within 2-3 weeks mainly by mechanism of epithelialization. However, it depends on the depth of the wounds and patient condition.
- Trial name
- NCT01553708
- Testing
- Epidermal growth factor with silver sulfadiazine cream, Silver zinc sulfadiazine cream
- Where
- Thailand
- Volunteers
- 34 people
- Sponsor
- Chulalongkorn University
Partial Epilepsy
Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR)
- Trial name
- NCT00908349
- Testing
- Oxcarbazepine XR
- Where
- 58 sites in United States, Bulgaria and 6 more
- Volunteers
- 214 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Fallopian Tubes Cancer, Ovarian Cancer
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab
The immune system of the body has the ability to fight and eliminate infections and cancers. Immune treatments, such as in this study, seek to teach the immune system to find and destroy cancer cells.
- Conditions
- Fallopian Tubes Cancer, Ovarian Cancer, Peritoneal Cancer
- Trial name
- NCT01223235
- Testing
- bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastroesophageal Reflux Disease (GERD)
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.
- Trial name
- NCT00394472
- Testing
- AZD3355
- Where
- 38 sites in Australia, Belgium and 6 more
- Volunteers
- 244 people
- Sponsor
- AstraZeneca
Major Depressive Disorder, Depression
Buprenorphine Used With Treatment Resistant Depression in Older Adults
The investigators are conducting a research study to learn about the safety and benefit of using a medication called buprenorphine for patients with difficult to treat depression.
- Trial name
- IRLGreyB (NCT02181231)
- Testing
- venlafaxine XR, buprenorphine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
HIV Infections
A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment
Our goal is to determine if a change in therapy to one containing Kaletra can improve the immune response in patients who have previously been immune partial responders or non-responders.
- Trial name
- NCT00145795
- Testing
- Kaletra + Current Dual NRTI Backbone, Current Regimen
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Atrophy of Edentulous Alveolar Ridge, Partial Edentulism
Comparing Conventional Dental Implants and Trabecular Metal™ Dental Implants After Sinus Floor Elevation
This is a research study to test the clinical outcome of Trabecular Metal™ Dental Implants (TMDI) (Zimmer Dental Inc Carlsbad, CA, US) in the Maxillary Sinus region.
- Trial name
- NCT02404649
- Testing
- Two implant designs in a Sinus Bone Augmentation Procedure, Two implant designs in a Sinus Floor Elevation Procedure
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Harvard Medical School (HMS and HSDM)
Osteoarthritis, Knee, Osteoarthritis, Hip
A Prospective Multicenter Longitudinal Cohort Study of the Mymobility Platform
Post-market prospective, multi-center longitudinal study to determine if mobile application-guided education and exercise paired with accurate and sensitive activity monitoring, captured from consumer wearables, can provide a…
- Trial name
- NCT03737149
- Testing
- mymobility with Apple Watch
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 6,559 people
- Sponsor
- Zimmer Biomet
Ovarian Cancer, Breast Cancer
Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum based Chemotherapy and Metastatic…
- Trial name
- SOLI (NCT04330040)
- Testing
- Olaparib
- Where
- 16 sites in India
- Volunteers
- 202 people
- Sponsor
- AstraZeneca
Epilepsy, Partial-onset Seizures
Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures
The purpose of this trial is to evaluate the safety and tolerability of long-term administration of Lacosamide at doses up to 400 mg/day in Japanese and Chinese adults with Epilepsy who have completed the Treatment and Transition…
- Trial name
- NCT01832038
- Testing
- Lacosamide
- Where
- 67 sites in China, Japan
- Volunteers
- 473 people
- Sponsor
- UCB Pharma SA
Epilepsy
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
The Sponsor wishes to develop brivaracetam as an anti-epileptic treatment in subjects 16 years and older with epilepsy. This study permits continued access to treatment for subjects who participated in a previous epilepsy study.
- Trial name
- NCT00761774
- Testing
- Brivaracetam
- Where
- 58 sites in United States, Australia and 9 more
- Volunteers
- 108 people
- Sponsor
- UCB Pharma
Asthma
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
To evaluate the dose-response of different doses of CHF 1531 pressurized metered dose inhaler (pMDI) containing formoterol fumarate, on lung function and other clinical outcomes and to identify the optimal dose(s) with regard to…
- Trial name
- FLASH (NCT03086460)
- Testing
- CHF 1531 pMDI, Formoterol Inhalation Solution
- Where
- 10 sites in United States
- Volunteers
- 67 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Epilepsy
This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment
This trial, evaluating the long-term safety and tolerability of brivaracetam will provide subjects suffering from epilepsy, who may have benefited from brivaracetam as adjunctive treatment, the opportunity to receive open label…
- Trial name
- NCT00150800
- Testing
- Brivaracetam
- Where
- 100 sites in United States, Australia and 4 more
- Volunteers
- 668 people
- Sponsor
- UCB PHARMA Inc. (US)
Schizophrenia
Efficacy of Pimozide Augmentation for Clozapine Partial Response
This is a 12 week outpatient study for patients with schizophrenia who are on Clozapine, but continue to experience symptoms. The purpose of this project is to find out if small doses of pimozide (an antipsychotic medication…
- Trial name
- NCT00374244
- Testing
- Pimozide
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Yale University